Literature DB >> 21372277

Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis.

Arash Afshari1, Jesper Brok, Ann M Møller, Jørn Wetterslev.   

Abstract

BACKGROUND: Acute hypoxemic respiratory failure, defined as acute lung injury and acute respiratory distress syndrome, are critical conditions associated with frequent mortality and morbidity in all ages. Inhaled nitric oxide (iNO) has been used to improve oxygenation, but its role remains controversial. We performed a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials (RCTs). We searched CENTRAL, Medline, Embase, International Web of Science, LILACS, the Chinese Biomedical Literature Database, and CINHAL (up to January 31, 2010). Additionally, we hand-searched reference lists, contacted authors and experts, and searched registers of ongoing trials. Two reviewers independently selected all parallel group RCTs comparing iNO with placebo or no intervention and extracted data related to study methods, interventions, outcomes, bias risk, and adverse events. All trials, irrespective of blinding or language status were included. Retrieved trials were evaluated with Cochrane methodology. Disagreements were resolved by discussion. Our primary outcome measure was all-cause mortality. We performed subgroup and sensitivity analyses to assess the effect of iNO in adults and children and on various clinical and physiological outcomes. We assessed the risk of bias through assessment of trial methodological components. We assessed the risk of random error by applying trial sequential analysis.
RESULTS: We included 14 RCTs with a total of 1303 participants; 10 of these trials had a high risk of bias. iNO showed no statistically significant effect on overall mortality (40.2%versus 38.6%) (relative risks [RR] 1.06, 95% confidence interval [CI] 0.93 to 1.22; I² = 0) and in several subgroup and sensitivity analyses, indicating robust results. Limited data demonstrated a statistically insignificant effect of iNO on duration of ventilation, ventilator-free days, and length of stay in the intensive care unit and hospital. We found a statistically significant but transient improvement in oxygenation in the first 24 hours, expressed as the ratio of Po₂ to fraction of inspired oxygen (mean difference [MD] 15.91, 95% CI 8.25 to 23.56; I² = 25%). However, iNO appears to increase the risk of renal impairment among adults (RR 1.59, 95% CI 1.17 to 2.16; I² = 0) but not the risk of bleeding or methemoglobin or nitrogen dioxide formation.
CONCLUSION: iNO cannot be recommended for patients with acute hypoxemic respiratory failure. iNO results in a transient improvement in oxygenation but does not reduce mortality and may be harmful.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372277     DOI: 10.1213/ANE.0b013e31820bd185

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  35 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  [Therapy of acute respiratory distress syndrome : Survey of German ARDS centers and scientific evidence].

Authors:  M Kredel; D Bierbaum; C Lotz; J Küstermann; N Roewer; R M Muellenbach
Journal:  Anaesthesist       Date:  2015-04-01       Impact factor: 1.041

3.  Early Use of Adjunctive Therapies for Pediatric Acute Respiratory Distress Syndrome: A PARDIE Study.

Authors:  Courtney M Rowan; Margaret J Klein; Deyin Doreen Hsing; Mary K Dahmer; Philip C Spinella; Guillaume Emeriaud; Amanda B Hassinger; Byron E Piñeres-Olave; Heidi R Flori; Bereketeab Haileselassie; Yolanda M Lopez-Fernandez; Ranjit S Chima; Steven L Shein; Aline B Maddux; Jon Lillie; Ledys Izquierdo; Martin C J Kneyber; Lincoln S Smith; Robinder G Khemani; Neal J Thomas; Nadir Yehya
Journal:  Am J Respir Crit Care Med       Date:  2020-06-01       Impact factor: 21.405

Review 4.  Acute lung failure.

Authors:  Rob Mac Sweeney; Daniel F McAuley; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2011-10-11       Impact factor: 3.119

5.  ATS Core Curriculum 2016: Part III. Pediatric Pulmonary Medicine.

Authors:  Debra Boyer; Carey C Thomson; Robyn Cohen; Devika Rao; Sharon Dell; Jonathan Rayment; Ruobing Wang; Fei J Dy; Jennifer Wambach; Jade Tam-Williams; Dawn Simon; Eric Price; Christopher M Oermann; Alvin Singh; Jordan S Rettig; Elizabeth D Duncan; Christopher D Baker; Deborah R Liptzin; Paul E Moore
Journal:  Ann Am Thorac Soc       Date:  2016-06

Review 6.  [Acute respiratory distress syndrome : Basic principles and treatment].

Authors:  P M Spieth; A Güldner; M Gama de Abreu
Journal:  Anaesthesist       Date:  2017-07       Impact factor: 1.041

Review 7.  Right ventricular dysfunction during acute respiratory distress syndrome and veno-venous extracorporeal membrane oxygenation.

Authors:  Jeroen J H Bunge; Kadir Caliskan; Diederik Gommers; Dinis Reis Miranda
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 8.  Sepsis: frontiers in supportive care, organisation and research.

Authors:  Anders Perner; Andrew Rhodes; Bala Venkatesh; Derek C Angus; Ignacio Martin-Loeches; Jean-Charles Preiser; Jean-Louis Vincent; John Marshall; Konrad Reinhart; Michael Joannidis; Steven M Opal
Journal:  Intensive Care Med       Date:  2017-01-27       Impact factor: 17.440

Review 9.  Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular immunotargeting.

Authors:  Makan Khoshnejad; Hamideh Parhiz; Vladimir V Shuvaev; Ivan J Dmochowski; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2018-03-06       Impact factor: 9.776

Review 10.  What is the clinical significance of pulmonary hypertension in acute respiratory distress syndrome? A review.

Authors:  P S Lai; C Mita; B T Thompson
Journal:  Minerva Anestesiol       Date:  2013-10-31       Impact factor: 3.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.